Updated: 1 day ago
In September 2026, researchers in Shanghai reported that a Chinese-developed drug called ivonescimab extended median survival to 30.8 months, versus 22.6 months with pembrolizumab (Keytruda), in previously untreated advanced lung cancer (ASCO Post, Sept 2026). Pembrolizumab is one of the most widely used cancer drugs in the world. Beating it head-to-head is rare.
That result is one reason international patients are looking at lung cancer treatment in China. Lung cancer is China's most common and deadliest cancer (Cancer incidence and mortality in China, 2022), and that scale has driven a wave of Chinese-developed drugs and trials.
The short answer: China offers several lung cancer drugs that are approved in China but not yet, or only recently, available elsewhere, plus experienced teams that helped set global standards. Whether any of them helps you depends on your tumor's biomarkers — especially EGFR mutations and PD-L1 level.
Key Takeaways |
|
Table of Contents
Why Your Biomarkers Decide Your Options
Most lung cancers are non-small cell lung cancer (NSCLC). Before choosing treatment, doctors test the tumor for "driver" mutations such as EGFR, ALK or MET, and measure PD-L1, a protein that predicts response to immunotherapy.
The tests used to guide treatment depend on the cancer type. For a separate example, see how breast cancer subtype shapes treatment options.
This matters more than geography. A drug that works for EGFR-mutated cancer will not help a tumor without that mutation. If your tumor hasn't had comprehensive molecular testing, that is the first step, wherever you are treated.
No Driver Mutation: Ivonescimab, a New Kind of Immunotherapy
What it is: ivonescimab is a bispecific antibody — it blocks PD-1 (like Keytruda) and VEGF (a signal tumors use to grow blood vessels) at the same time. It was developed in China.
The evidence: the HARMONi-2 phase III trial, led by Prof. Caicun Zhou at Shanghai East Hospital, Tongji University, randomized 398 patients with untreated advanced NSCLC, PD-L1 of at least 1%, and no EGFR or ALK alterations. Compared with pembrolizumab, ivonescimab:
Nearly doubled median progression-free survival: 11.1 vs. 5.8 months
Improved median overall survival: 30.8 vs. 22.6 months (hazard ratio 0.73)
Serious treatment-related side effects were somewhat more common (29.9% vs. 21.6%), though discontinuation rates were similar (ASCO Post, Sept 2026).
Status: approved in China for this population since April 2025.
Limitations: all patients were enrolled in China. Results may not transfer exactly to other populations, and the survival data were first presented at a conference.
EGFR-Mutated Lung Cancer: Where China Helped Set the Standard
EGFR mutations are found in a much larger share of lung cancers in East Asian patients than in Western patients, which has made China a center for EGFR research.
After surgery: osimertinib (ADAURA). Prof. Yi-Long Wu of the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, was a corresponding author of the global ADAURA phase III trial. Osimertinib after surgery raised five-year overall survival to 88% versus 78% with placebo in stage IB–IIIA EGFR-mutated NSCLC (ASCO Post, July 2023; NEJM). This is now standard care worldwide, not a China-only option.
Advanced disease: furmonertinib (FURLONG). Furmonertinib is a Chinese-developed third-generation EGFR drug. In the FURLONG phase III trial, led by Prof. Yuankai Shi at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences, 358 patients received furmonertinib or gefitinib first-line. Median progression-free survival was 20.8 vs. 11.1 months (Lancet Respiratory Medicine, 2022).
Be careful with the comparison: FURLONG compared furmonertinib with gefitinib, an older drug, not with osimertinib, today's international first-line standard. There's no head-to-head evidence that furmonertinib is better than osimertinib. The trial was funded by its developer, Shanghai Allist.
EGFR Exon 20 Insertions: A Chinese Drug Now Approved in the US
EGFR exon 20 insertions are a rarer subtype that responds poorly to standard EGFR drugs. Sunvozertinib, developed by China-based Dizal, received US FDA accelerated approval in July 2025 for patients whose disease progressed after platinum chemotherapy. In the WU-KONG1b trial, 46% of patients responded, with a median response duration of 11.1 months (OncLive, July 2025).
What this means for you: this is one example of a Chinese drug that may now be accessible at home as well. Ask your oncologist before assuming you need to travel.
After Standard Treatment Fails: TIL Therapy and Cancer Vaccines in Hainan Boao Lecheng
For patients whose lung cancer has progressed after targeted therapy, immunotherapy and chemotherapy, the most-discussed next options are cell therapies and personalized vaccines. These are investigational for lung cancer almost everywhere. China offers one unusual route to them.
What Boao Lecheng is. The Hainan Boao Lecheng International Medical Tourism Pilot Zone is a special medical zone on Hainan Island where hospitals may use some treatments approved overseas but not yet approved in mainland China. It has introduced more than 500 such drugs and devices and served more than 200,000 patients (Xinhua, Jan 2026). More than 30 hospitals operate there, including West China Lecheng Hospital of Sichuan University and Ruijin Hainan Hospital, the Hainan branch of Shanghai's Ruijin Hospital (SCMP).
TIL therapy (tumor-infiltrating lymphocytes). TIL therapy takes immune cells from a patient's own tumor, multiplies them in the lab and infuses them back. In lung cancer, the most advanced data come from the US product lifileucel: in 69 patients who had already received chemotherapy and immunotherapy, 24.6% responded, rising to 43.3% in patients without a KRAS mutation (Iovance, Oct 2026). Lifileucel is approved only for melanoma; for lung cancer it remains investigational. In mainland China, Shanghai Chest Hospital launched a trial of the Chinese TIL product GC101 in October 2024 for driver-mutation-positive NSCLC after targeted therapy and chemotherapy failed (Pharnex Cloud, Oct 2024).
DC vaccines and personalized cancer vaccines. Dendritic cell (DC) vaccines train the immune system to recognize a patient's tumor-specific proteins (neoantigens). A personalized neoantigen DC vaccine co-developed by Likang Life Sciences and Sichuan University is in phase I trials for pancreatic and liver cancer (Pharmacodia). At West China Lecheng Hospital, a patient with early-stage lung cancer received LK101, a personalized mRNA cancer vaccine intended to lower the risk of relapse (SCMP).
Be realistic. These treatments are early-stage for most lung cancer patients. Response rates in TIL studies are measured in the tens of percent, not most patients, and published lung cancer data for DC vaccines are limited. Costs are typically paid out of pocket. They are worth asking about mainly after standard options are exhausted, and only after a specialist confirms your tumor and health status fit the program's requirements. Not every program accepts international patients, so availability must be confirmed case by case.
Hospitals and Specialists Behind These Advances
The hospitals below are listed because they led one of the trials above, not as a general ranking.
Shanghai East Hospital, Tongji University
Guangdong Provincial People’s Hospital / Guangdong Lung Cancer Institute
National Cancer Center / Cancer Hospital, CAMS
Specialists Behind the Research
Photos and profiles: Shanghai East Hospital, Tongji University, Guangdong Provincial People’s Hospital and CAMS. Confirm current appointments and international-patient access directly.
China's Lung Cancer Options at a Glance
Not in the table: TIL therapy and personalized DC or mRNA vaccines, because for lung cancer they are investigational rather than approved options. See the Boao Lecheng section above.
How Much Does Lung Cancer Treatment in China Cost?
ChinaCureLink's general planning range for solid tumor treatment, including lung cancer, is US$20,000–$50,000. This is an internal budget estimate, not a hospital quote or a verified average for lung cancer. Your actual cost depends on your diagnosis, treatment plan, drug cycles and length of stay. The table also shows the separate general range for advanced blood cancer treatment for context.
What a hospital quote usually covers: treatment, medicines given in hospital, scans and tests during treatment, and your inpatient stay. What it often leaves out: take-home drugs, treatment of complications, extra cycles if your plan changes, and your travel, hotel and caregiver costs. Always ask for an itemized estimate and what is excluded.
Ways to keep costs predictable:
Get a written estimate before you travel, based on your actual records.
Ask about international patient discounts. When a hospital sends you a quote, ChinaCureLink helps you apply for any international patient discount it offers.
Budget for long-term drugs. Many newer drugs are taken for months. If a drug is approved only in China, plan how you'll pay for and receive refills after you return home.
Check your insurance. Most international health plans don't cover treatment in China, and China's national insurance doesn't cover foreign patients.
What International Lung Cancer Patients Should Know Before Traveling
Long-term drugs need a long-term plan. Targeted drugs and immunotherapy are usually given for many months. If a drug isn't approved in your country, ask how you would continue it after returning home, and who would monitor side effects.
If you’re helping someone with breast cancer plan care instead, use the breast cancer treatment access guide for their separate pathway.
Old test results may not be enough. Lung cancers can change after treatment, especially EGFR-mutated tumors that develop resistance. Chinese specialists may ask for a new biopsy or a liquid biopsy before recommending a drug.
A promising headline isn't the same as eligibility. HARMONi-2, for example, excluded patients with EGFR or ALK alterations. Each approval covers a specific group.
Independent Guidance Before You Travel
ChinaCureLink (chinacurelink.com), a Medebound HEALTH company, is an independent medical facilitator and patient advocate helping international patients explore serious disease treatment in the US or in China. It was founded by physicians 10 years ago and has helped around 3,000 international patients.
For lung cancer, the most valuable step is often interpreting your biomarker report against what's approved in China versus at home. ChinaCureLink reviews your pathology, molecular results and treatment history, can match your case with up to three relevant Chinese hospitals, and can arrange a video second opinion with a Chinese lung cancer specialist before you decide whether to travel. Applying and hospital and specialist matching are free. The video second opinion is a paid consultation, and its fee is confirmed with you before booking.
You Contact the Hospital vs. via ChinaCureLink
Both routes can work. Many large Chinese hospitals have international departments, and some patients go direct. Here is what each route looks like, step by step.
When going direct may be enough: you have lived in China, you can handle records and communication, and you mainly need an appointment. When guided help adds most: you're unsure which treatment or hospital fits, your case is complex or rare, you want a specialist's opinion before deciding to travel, or you prefer to have an on-site medical interpretor and guide.
Your Next Steps
For the practical steps from records review to follow-up, read how to get lung cancer treatment in China.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Is lung cancer treatment in China better than in the US?
Not across the board. Standard care is broadly similar at leading centers in both countries. China's advantage is in specific drugs , such as ivonescimab, that are approved there but may not be available elsewhere yet.
Is ivonescimab available outside China?
As of our sources, ivonescimab is approved in China. Its approval status in the US and Europe should be checked at the time you read this, as regulatory reviews are ongoing.
Can I get EGFR-targeted therapy in China if I've already had osimertinib?
Possibly, depending on the resistance mechanism. A new biopsy or liquid biopsy is usually needed to identify why the cancer progressed before choosing the next treatment.
What records should I prepare?
Pathology report, full molecular test report (EGFR, ALK, ROS1, MET, KRAS, PD-L1 and others), recent CT/PET and brain MRI, and a dated list of treatments and responses.
The Bottom Line
China has produced meaningful lung cancer advances: a bispecific immunotherapy that outperformed pembrolizumab in a phase III trial, homegrown EGFR drugs, and leadership in trials that set global standards. But each advance applies to a specific biomarker group, and some are already available outside China.
The right first step is a specialist review of your molecular results to see whether any Chinese option offers something you can't get at home.
Sources and Further Reading
ChinaCureLink internal treatment-budget estimates, supplied November 2026: US$20,000–$50,000 for solid tumors; US$80,000+ for advanced blood cancers. Planning ranges, not individual hospital quotes.
Medical Disclaimer
This article provides general information and does not replace individual medical advice. Eligibility, treatment access, risks, fees and follow-up require specialist assessment. Research findings do not guarantee outcomes. Confirm current access directly with the treating hospital before travel.
